Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 7.4% – Should You Buy?

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) were up 7.4% on Friday . The stock traded as high as $5.93 and last traded at $5.9950. Approximately 188,256 shares were traded during trading, a decline of 93% from the average daily volume of 2,635,431 shares. The stock had previously closed at $5.58.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on TSHA shares. Chardan Capital reaffirmed a “buy” rating and set a $12.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, March 19th. Needham & Company LLC increased their price objective on Taysha Gene Therapies from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, March 19th. Truist Financial raised Taysha Gene Therapies to a “strong-buy” rating in a research note on Wednesday, March 25th. Canaccord Genuity Group increased their price objective on Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, April 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Friday, March 27th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $11.64.

Taysha Gene Therapies Trading Up 2.3%

The company has a 50 day moving average of $5.77 and a 200 day moving average of $5.17. The company has a debt-to-equity ratio of 0.23, a quick ratio of 14.04 and a current ratio of 14.04. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of -15.03 and a beta of 1.19.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). On average, research analysts predict that Taysha Gene Therapies, Inc. will post -0.5 EPS for the current fiscal year.

Insider Activity

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction on Friday, April 10th. The stock was sold at an average price of $4.46, for a total value of $892,000.00. Following the completion of the sale, the insider directly owned 1,136,410 shares of the company’s stock, valued at $5,068,388.60. This trade represents a 14.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.78% of the stock is owned by company insiders.

Institutional Trading of Taysha Gene Therapies

Hedge funds and other institutional investors have recently modified their holdings of the stock. Marex Group plc acquired a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth $29,000. E Fund Management Co. Ltd. acquired a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new stake in shares of Taysha Gene Therapies in the 3rd quarter worth $40,000. Tower Research Capital LLC TRC increased its stake in shares of Taysha Gene Therapies by 156.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after acquiring an additional 10,742 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its stake in shares of Taysha Gene Therapies by 143.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock worth $43,000 after acquiring an additional 4,607 shares during the last quarter. 77.70% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.